ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS Group
ALX Oncology (NASDAQ:ALXO – Get Free Report) had its price objective cut by UBS Group from $4.00 to $2.20 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price would indicate a potential upside of 51.20% from the stock’s current price. […]
More Stories
Porsche Recalls More than 173,500 Vehicles for Rear-Camera Malfunction
By Rob Sabo Porsche Cars North America, Inc. has issued a recall of 173,538 vehicles manufactured during the past six...
Chief Justice Roberts Says Americans Continue to Admire the Constitution
By Matthew Vadum Chief Justice John Roberts said on Dec. 31 that as the United States prepares to celebrate its...
US Rings in New Year as the World Welcomes 2026
By Troy Myers and Joseph Lord The East Coast rang in 2026 as the clock struck midnight on New Year’s...
500 Illegal Immigrants Arrested in Minnesota, 1,000 Immigration-Fraud Cases Investigated: DHS Official
By Janice Hisle As additional investigators surge to fraud-plagued Minnesota, federal agents have already arrested 500 illegal immigrants and probed...
Oil Glut Pushes Prices Down, Easing Inflation in 2025—What’s Ahead
By Panos Mourdoukoutas Rising global inventories weighed on oil markets in 2025, crushing prices and helping push headline inflation lower....
California Delays Revoking 17,000 CDLs Until March After Immigrants Sue
By Jill McLaughlin California announced on Dec. 30 it would delay revoking 17,000 commercial driver’s licenses (CDLs) until March after...